Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 10
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Kulasingam, Shalini and Havrilesky, Laura 2012. Health economics of screening for gynaecological cancers. Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 26, Issue. 2, p. 163.


    Sroczynski, G. Schnell-Inderst, P. Mühlberger, N. Lang, K. Aidelsburger, P. Wasem, J. Mittendorf, T. Engel, J. Hillemanns, P. Petry, K.U. Krämer, A. and Siebert, U. 2011. Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis. European Journal of Cancer, Vol. 47, Issue. 11, p. 1633.


    van Rosmalen, J de Kok, IMCM and van Ballegooijen, M 2012. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG: An International Journal of Obstetrics & Gynaecology, Vol. 119, Issue. 6, p. 699.


    Berkhof, Johannes Coupé, Veerle M. Bogaards, Johannes A. van Kemenade, Folkert J. Helmerhorst, Theo J. Snijders, Peter J. and Meijer, Chris J. 2010. The health and economic effects of HPV DNA screening in The Netherlands. International Journal of Cancer, Vol. 127, Issue. 9, p. 2147.


    Kárpáti, Krisztián and Sándor, János 2009. Development of health technology assessment in Central Europe. International Journal of Technology Assessment in Health Care, Vol. 25, Issue. 04, p. 596.


    Levi, José E. Longatto-Filho, Adhemar Eluf-Neto, José Rodrigues, Célia L. Oliveira, Cristina M. Carloni, Adriana C. Lorenzi, Adriana T. Tacla, Maricy Fregnani, José H. Ab’Saber, Alexandre M. Scapulatempo, Cristovam and Villa, Luisa L. 2014. Evaluation of HPV Molecular Tests in Primary Screening for Cervical Cancer in Brazil. Open Journal of Obstetrics and Gynecology, Vol. 04, Issue. 08, p. 470.


    Dewilde, Sarah Brüggenjürgen, Bernd Nienaber, Christoph Senges, Jochen Welte, Robert and Willich, Stefan N. 2012. Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany. The European Journal of Health Economics, Vol. 13, Issue. 4, p. 381.


    Chen, Meng-Kan Hung, Hui-Fang Duffy, Stephen Yen, Amy Ming-Fang and Chen, Hsiu-Hsi 2011. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. Journal of Evaluation in Clinical Practice, Vol. 17, Issue. 6, p. 1050.


    O’Mahony, James F. Naber, Steffie K. Normand, Charles Sharp, Linda O’Leary, John J. and de Kok, Inge M.C.M. 2015. Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. Value in Health, Vol. 18, Issue. 8, p. 1138.


    Chow, I H-I Tang, C-H You, S-L Liao, C-H Chu, T-Y Chen, C-J Chen, C-A and Pwu, R-F 2010. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. British Journal of Cancer, Vol. 103, Issue. 12, p. 1773.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 24, Issue 2
  • April 2008, pp. 184-192

Cost-effectiveness of primarily human papillomavirus–based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health

  • Nikolai Mühlberger (a1), Gaby Sroczynski (a1), Eva Esteban (a1), Thomas Mittendorf (a2), Rebecca A. Miksad (a3) and Uwe Siebert (a4)
  • DOI: http://dx.doi.org/10.1017/S0266462308080264
  • Published online: 01 April 2008
Abstract

Objectives: The aim of this study was to summarize the current evidence for the cost-effectiveness of primarily human papillomavirus (HPV) -based cervical cancer screening in settings with already established Papanicolaou test (Pap) programs. Emphasis was placed on the German situation with annual Pap screening.

Methods: Medical, economic, and health technology assessment (HTA) databases were systematically searched for cost-effectiveness studies comparing HPV to Pap screening. Study data were extracted, standardized, and summarized in cost-effectiveness plots contrasting HPV strategies to Pap screening with 1-, 2-, 3-, and 5-years interval. For each Pap setting, the likelihood of cost-effective HPV screening was assessed depending on willingness-to-pay.

Results: We reviewed twelve decision-analytic cost-effectiveness models. Study results showed wide variation due to methodical heterogeneity. Data synthesis revealed that the cost-effectiveness of HPV screening depends on the interval of the established Pap screening strategy. In comparison with Pap screening every 2 years, only 25 percent of the HPV-based screening strategies were cost-effective. However, in comparison with Pap screening every 1, 3, or 5 years, 83 percent, 55 percent, and 92 percent of HPV screening strategies were cost-effective, respectively. Results for settings with annual Pap screening are based on models assuming 100 percent screening coverage.

Conclusions: The introduction of HPV-based screening programs is cost-effective if the screening interval of the established Pap program exceeds 2 years. In settings with biennial Pap screening, introduction of HPV-based screening is unlikely to be cost-effective. Results also suggest cost-effectiveness of HPV-based screening in settings with annual Pap screening; however, this finding should be confirmed under realistic screening adherence assumptions.

Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.FX Bosch , A Lorincz , N Munoz , CJ Meijer , KV Shah . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244265.

2.P Boyle , P Maisonneuve , P Autier . Update on cancer control in women. Int J Gynaecol Obstet. 2000;70:263303.

3.C Clavel , M Masure , JP Bory , Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women. Br J Cancer. 2001;84:16161623.

4.J Cuzick , E Beverley , L Ho , HPV testing in primary screening of older women. Br J Cancer. 1999;81:554558.

6.J Cuzick , A Szarewski , H Cubie , Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet. 2003;362:18711876.

7.A Gandjour , KW Lauterbach . [Cost-effectiveness of quality improvement measures in health care]. Med Klin (Munich). 2002;97:499502.

8.SJ Goldie , JJ Kim , TC Wright . Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619631.

9.L Gustafsson , J Ponten , M Zack , HO Adami . International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755763.

10.JW Henderson . Cost-effectiveness of cervical cancer screening strategies. Expert Rev Pharmacoeconom Outcomes Res. 2004;4:287296.

11.J Holmes , L Hemmett , S Garfield . The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ. 2005;6:3037.

13.JJ Kim , TC Wright , SJ Goldie . Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97:888895.

14.JS Mandelblatt , WF Lawrence , SM Womack , Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:23722381.

16.T Mittendorf , KU Petry , T Iftner , W Greiner , JM von der Schulenburg . Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ. 2003;4:209215.

17.N Munoz , FX Bosch , S de Sanjose , Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518527.

18.K Nanda , DC McCrory , ER Myers , Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med. 2000;132:810819.

19.P Nieminen , M Kallio , M Hakama . The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol. 1995;85:10171021.

21.KU Petry , S Menton , M Menton , Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8466 patients. Br J Cancer. 2003;88:15701577.

23.PD Sasieni , J Cuzick , E Lynch-Farmery . Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer. 1996;73:10011005.

24.U Schenck , L von Karsa . Cervical cancer screening in Germany. Eur J Cancer. 2000;36:22212226.

25.M Schiffman , R Herrero , A Hildesheim , HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA. 2000;283:8793.

26.A Schneider , H Hoyer , B Lotz , Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529534.

27.C Sherlaw-Johnson , S Gallivan . The planning of cervical cancer screening programmes in eastern Europe: Is viral testing a suitable alternative to smear testing? Health Care Manag Sci. 2000;3:323329.

28.C Sherlaw-Johnson , Z Philips . An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer. 2004;91:8491.

30.DN Slater , PC Milner , H Radley . Audit of deaths from cervical cancer: Proposal for an essential component of the National Screening Programme. J Clin Pathol. 1994;47:2728.

31.M van Ballegooijen , ME Van Den Akker-van Marle , PG Warmerdam , CJ Meijer , JM Walboomers , JD Habbema . Present evidence on the value of HPV testing for cervical cancer screening: A model-based exploration of the (cost-)effectiveness. Br J Cancer. 1997;76:651657.

32.JM Walboomers , MV Jacobs , MM Manos , Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:1219.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
UNKNOWN
Supplementary Materials

Muhlberger supplementary material
Supplementary table

 Unknown (186 KB)
186 KB
UNKNOWN
Supplementary Materials

Muhlberger supplementary material
Supplementary table

 Unknown (104 KB)
104 KB